348 related articles for article (PubMed ID: 30628100)
1. Cross-sectional multicenter observational study of psoriatic arthritis in Japanese patients: Relationship between skin and joint symptoms and results of treatment with tumor necrosis factor-α inhibitors.
Tsuruta N; Narisawa Y; Imafuku S; Ito K; Yamaguchi K; Miyagi T; Takahashi K; Fukamatsu H; Morizane S; Koketsu H; Yamaguchi M; Hino R; Nakamura M; Ohyama B; Ohata C; Kuwashiro M; Sato T; Saito K; Kaneko S; Yonekura K; Hayashi H; Yanase T; Morimoto K; Sugita K; Yanagihara S; Kikuchi S; Mitoma C; Nakahara T; Furue M; Okazaki F
J Dermatol; 2019 Mar; 46(3):193-198. PubMed ID: 30628100
[TBL] [Abstract][Full Text] [Related]
2. The Role of Tumor Necrosis Factor-α Blockers in Psoriatic Disease. Therapeutic Options in Psoriatic Arthritis.
Addimanda O; Possemato N; Caruso A; Pipitone N; Salvarani C
J Rheumatol Suppl; 2015 Nov; 93():73-8. PubMed ID: 26523063
[TBL] [Abstract][Full Text] [Related]
3. Treatment of psoriatic arthritis with biological agents.
Ceponis A; Kavanaugh A
Semin Cutan Med Surg; 2010 Mar; 29(1):56-62. PubMed ID: 20430309
[TBL] [Abstract][Full Text] [Related]
4. Role of Agents other than Tumor Necrosis Factor Blockers in the Treatment of Psoriatic Arthritis.
Atzeni F; Costa L; Caso F; Scarpa R; Sarzi-Puttini P
J Rheumatol Suppl; 2015 Nov; 93():79-81. PubMed ID: 26523064
[TBL] [Abstract][Full Text] [Related]
5. Psoriatic arthritis: current therapy and future approaches.
Huynh D; Kavanaugh A
Rheumatology (Oxford); 2015 Jan; 54(1):20-8. PubMed ID: 25125588
[TBL] [Abstract][Full Text] [Related]
6. Anti-TNFα-therapy as an evidence-based treatment option for different clinical manifestations of psoriatic arthritis.
Köhm M; Burkhardt H; Behrens F
Clin Exp Rheumatol; 2015; 33(5 Suppl 93):S109-14. PubMed ID: 26472504
[TBL] [Abstract][Full Text] [Related]
7. Elderly psoriatic arthritis patients on TNF-α blockers: results of an Italian multicenter study on minimal disease activity and drug discontinuation rate.
Costa L; Lubrano E; Ramonda R; Chimenti MS; Vezzù M; Perrotta FM; Del Puente A; Peluso R; Bottiglieri P; Lorenzin M; Sunzini F; Darda MA; Fiocco U; Perricone R; Punzi L; Scarpa R; Caso F
Clin Rheumatol; 2017 Aug; 36(8):1797-1802. PubMed ID: 28589323
[TBL] [Abstract][Full Text] [Related]
8. Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs.
Perrotta FM; Marchesoni A; Lubrano E
J Rheumatol; 2016 Feb; 43(2):350-5. PubMed ID: 26669925
[TBL] [Abstract][Full Text] [Related]
9. Treatment of psoriatic arthritis with tumor necrosis factor inhibitors: longer-term outcomes including enthesitis and dactylitis with golimumab treatment in the Longterm Extension of a Randomized, Placebo-controlled Study (GO-REVEAL).
Kavanaugh A; Mease P
J Rheumatol Suppl; 2012 Jul; 89():90-3. PubMed ID: 22751603
[TBL] [Abstract][Full Text] [Related]
10. Four cases of Japanese patients with psoriatic arthritis in whom effective treatments by anti-tumor necrosis factor-α drugs were evaluated by magnetic resonance imaging together with improvement of skin lesions.
Yonenaga T; Saeki H; Nakagawa H; Fukuchi O; Umezawa Y; Hayashi M; Ito T; Yanaba K; Tojyo S; Fukuda K
J Dermatol; 2015 Jan; 42(1):49-55. PubMed ID: 25425546
[TBL] [Abstract][Full Text] [Related]
11. New Approaches in Tumor Necrosis Factor Antagonism for the Treatment of Psoriatic Arthritis: Certolizumab Pegol.
Cauli A; Piga M; Lubrano E; Marchesoni A; Floris A; Mathieu A
J Rheumatol Suppl; 2015 Nov; 93():70-2. PubMed ID: 26523062
[TBL] [Abstract][Full Text] [Related]
12. Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies.
Elyoussfi S; Thomas BJ; Ciurtin C
Rheumatol Int; 2016 May; 36(5):603-12. PubMed ID: 26892034
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Dactylitis and Enthesitis in Psoriatic Arthritis with Biologic Agents: A Systematic Review and Metaanalysis.
Mourad A; Gniadecki R
J Rheumatol; 2020 Jan; 47(1):59-65. PubMed ID: 30824641
[TBL] [Abstract][Full Text] [Related]
14. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.
Tobin AM; Kirby B
BioDrugs; 2005; 19(1):47-57. PubMed ID: 15691217
[TBL] [Abstract][Full Text] [Related]
15. An overview of low disease activity and remission in psoriatic arthritis.
Lubrano E; Perrotta FM; Kavanaugh A
Clin Exp Rheumatol; 2015; 33(5 Suppl 93):S51-4. PubMed ID: 26470835
[TBL] [Abstract][Full Text] [Related]
16. Need for Improvement in Current Treatment of Psoriatic Arthritis: Study of an Outpatient Clinic Population.
Michelsen B; Diamantopoulos AP; Høiberg HK; Soldal DM; Kavanaugh A; Haugeberg G
J Rheumatol; 2017 Apr; 44(4):431-436. PubMed ID: 28148701
[TBL] [Abstract][Full Text] [Related]
17. TNF-alpha inhibitors for the six treatment targets of psoriatic arthritis.
Lubrano E; Scriffignano S; Perrotta FM
Expert Rev Clin Immunol; 2019 Dec; 15(12):1303-1312. PubMed ID: 31652079
[No Abstract] [Full Text] [Related]
18. Progress in understanding and utilizing TNF-α inhibition for the treatment of psoriatic arthritis.
Caso F; Lubrano E; Del Puente A; Caso P; Peluso R; Foglia F; Benigno C; Girolimetto N; Bottiglieri P; Scarpa R; Costa L
Expert Rev Clin Immunol; 2016; 12(3):315-31. PubMed ID: 26558483
[TBL] [Abstract][Full Text] [Related]
19. Switching biologics in the treatment of psoriatic arthritis.
Merola JF; Lockshin B; Mody EA
Semin Arthritis Rheum; 2017 Aug; 47(1):29-37. PubMed ID: 28363434
[TBL] [Abstract][Full Text] [Related]
20. Use of biological drugs in patients with psoriasis and psoriatic arthritis in Italy: Results from the PSONG survey.
Potenza MC; Peris K; Berardesca E; Bianchi L; Richetta A; Bernardini N; De Simone C; Teoli M; Zangrilli A; D'epiro S; Orsini D; Narcisi A; Chimenti S; Costanzo A
Dermatol Ther; 2018 Jan; 31(1):. PubMed ID: 29215183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
